Ashley Sumrall, MD, neuro-oncologist

Stuart Burri, MD, radiation oncologist

Carolinas HealthCare System’s Levine Cancer Institute is one of only 150 cancer centers in the nation to offer an innovative treatment for patients with glioblastoma—the most deadly type of brain cancer.

The technology, NovoTTF, is a wearable device that delivers electric fields to a patient’s brain via ceramic disks, which are attached to the scalp.  NovoTTF recently became FDA-approved for its success in reducing the size of brain tumors and prolonging survival in patients with glioblastoma.

“This is a very personalized type of medicine, which could truly be a game-changer for patients who think they have exhausted all other options,” said Ashley Sumrall, MD, neuro-oncologist at the Institute.

Dr. Sumrall, along with Stuart Burri, MD, radiation oncologist, are principal investigator and co-principal investigator on a clinical trial testing NovoTTF patients with unresectable glioblastoma, in which chemotherapy and radiation treatment mechanisms are not sufficient.  

The Institute is the only site in the nation enrolling patients in the trial, which is only available in Charlotte and at Roper St. Francis in Charleston, SC.